Clinical Trial Update: Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients

View source ↗

Summary

Completed clinical trial evaluating the Miti-gene Recurrence Score in HR+/HER2- breast cancer patients in China.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: Sun Yat-sen University | Conditions: Breast Cancer | Status: COMPLETED